Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Editorial board130
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study91
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) 88
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials81
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement76
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study70
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage64
Uterine cancer incidence overtakes colorectal cancer, disproportionately impacting minority women in the United States62
Molecular testing in the upfront setting for high-grade endometrial cancer: How are we doing?62
Quantifying opportunities to reduce high-grade serous ovarian cancer via opportunistic salpingectomy61
Ovarian-Adnexal Reporting and Data System (O-RADS) for adnexal masses: Are we hitting the mark?60
Investigating the role of the poly (ADP-ribose) polymerase enzyme family in cervical cancer pathogenesis60
Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study56
Obesity and ovarian cancer: Leveraging real-world data for incidence and outcomes using a multicenter nationwide electronic database56
A phase I, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (Claudin 6 x CD3) T-cell engaging bispecific antibody in advanced solid tumors54
Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years52
Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-diethylstilbestrol era50
(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-30549
2025 Annual Meeting on Women's Cancer – SGO Meeting Insights49
Prognosis of patients who become pregnant after achieving a complete response with fertility-sparing treatment in early endometrial cancer: A Gynecologic Oncology Research Investigators Collaboration 48
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study48
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)48
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor46
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA12546
ChatGPT vs Google: Understanding a patient's perspective on their cancer diagnosis, recommended treatment, and survival outcomes43
Racial disparities in human papillomavirus vaccination rates and correlation with cervical cancer stage at diagnosis: A retrospective analysis43
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial43
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer42
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)41
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)40
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)39
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)37
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)37
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)37
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)37
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis36
0.6193380355835